Fierce Pharma

ACIP member's miscommunication on vaccine panel's future adds to confusion after court ruling

The status of the CDC’s vaccine advisory panel was thrown into further disarray this week after an outspoken member of the Advisory Committee on Immunization Practices (ACIP)—whose appointment was ...
Fierce Pharma

With Novo's semaglutide going off patent, Indian drugmakers set to launch their cheaper generics

With patents expiring today in India for Novo Nordisk’s popular diabetes and obesity drugs Ozempic and Wegovy, more than 40 makers of generic drugs are expected to begin launching their cheaper ...
Fierce Pharma

Rhythm's Imcivree scores 'transformative' FDA approval in brain-damage related obesity

Rhythm Pharmaceuticals is switching up the tempo for its melanocortin-4 receptor (MC4R) agonist Imcivree. | The new FDA nod makes Rhythm Pharma's Imcivree the first approved drug for acquired ...
Fierce Pharma

CSL warns of supply shortfall, treatment delays for hemophilia gene therapy Hemgenix

The last available hemophilia gene therapy is temporarily unavailable, according to CSL Behring.  | The company is working ...
Fierce Pharma

Fierce Pharma Asia—World's 1st brain chip nod; AZ's cell therapy bet; Astellas-CytomX breakup

China has approved the world's first commercial brain-computer interface. AstraZeneca is building new cell therapy centers in Shanghai. | China approved the world's first commercial brain-computer ...
Fierce Pharma

Novo’s Wegovy HD passes muster under FDA national priority voucher program

Still basking in the afterglow of its Wegovy pill launch earlier this year, Novo has achieved another victory as it strives to make the most out of its blockbuster GLP-1 drug in an increasingly ...
Fierce Pharma

Maryland bill calls for more transparency in pharma’s disease awareness campaigns

A new bill introduced in the Maryland House of Delegates requests that pharmas be more specific about the brands related to ...
Fierce Pharma

AstraZeneca to build cell therapy manufacturing hub, R&D center in Shanghai

Following through with its sizable investment commitment in China, AstraZeneca on Thursday unveiled plans to build a commercial cell therapy manufacturing base and an innovation center dedicated to | ...
Fierce Pharma

After Alfasigma's GSK licensing deal, Lynavoy picks up FDA nod in rare liver disease

Alfasigma’s buzzer-beater bet on GSK’s rare liver disease prospect has paid off. | Lynavoy is now the first FDA-approved product that can treat cholestatic pruritus in patients with primary biliary ...
Fierce Pharma

Sandoz expands biosim collab with Samsung Bioepis, sets sights on Takeda's Entyvio

Sandoz has struck a deal with Samsung Bioepis to partner on up to five biosimilars, with the first being SB36, a copycat of ...
Fierce Pharma

BMS brings 'Emily in Paris' star and cancer survivor Ashley Park aboard campaign honoring oncologists

Bristol Myers Squibb has added a familiar face to an ongoing initiative to thank oncologists for the valuable time they ...
Fierce Pharma

Pfizer eyes earlier Talzenna use after phase 3 prostate cancer win

Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). | After an FDA snub in a broader metastatic ...